Neoadjuvant Chemotherapy for Osteosarcoma of the Extremity: Intensification of Preoperative Treatment Does Not Increase the Rate of Good Histologic Response to the Primary Tumor or Improve the Final Outcome

Gaetano Bacci, Cristiana Forni, Stefano Ferrari, Alessandra Longhi, Franco Bertoni, Mario Mercuri, Davide Donati, Rodolfo Capanna, Gabriella Bernini, Antonio Briccoli, Elisabetta Setola, Michela Versari

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of this study was to compare the results in terms of histologic response to primary chemotherapy of two sequential studies in osteosarcoma patients preoperatively treated with methotrexate, doxorubicin, cisplatin, and ifosfamide, given at different doses Patients and Methods: Between January 1993 and March 1995, 171 patients with osteosarcoma of the extremity were treated according to a protocol of neoadjuvant chemotherapy with preoperative methotrexate, cisplatin, doxorubicin, and ifosfamide. From April 1995 to December 1999, 196 osteosarcoma patients were preoperatively treated with the same drugs at higher doses. Postoperatively, patients received the same treatment in both studies used, but poor responders (tumor necrosis

Original languageEnglish
Pages (from-to)845-853
Number of pages9
JournalJournal of Pediatric Hematology/Oncology
Volume25
Issue number11
DOIs
Publication statusPublished - Nov 2003

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Neoadjuvant Chemotherapy for Osteosarcoma of the Extremity: Intensification of Preoperative Treatment Does Not Increase the Rate of Good Histologic Response to the Primary Tumor or Improve the Final Outcome'. Together they form a unique fingerprint.

  • Cite this